Sona Nanotech Inc
Sona Nanotech Inc. operates as a nanotechnology life sciences company. It develops targeted hyperthermia and nanomedical therapies for the treatment of cancer. The company also develops gold nanoparticle products; lateral flow assay rapid tests; and bovine TB and concussion tests. Sona Nanotech Inc. is based in Halifax, Canada.
Sona Nanotech Inc (SNANF) - Net Assets
Latest net assets as of April 2025: $1.01 Million USD
Based on the latest financial reports, Sona Nanotech Inc (SNANF) has net assets worth $1.01 Million USD as of April 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.29 Million) and total liabilities ($1.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.01 Million |
| % of Total Assets | 44.2% |
| Annual Growth Rate | -0.81% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 475.36 |
Sona Nanotech Inc - Net Assets Trend (2016–2024)
This chart illustrates how Sona Nanotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sona Nanotech Inc (2016–2024)
The table below shows the annual net assets of Sona Nanotech Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-10-31 | $2.51 Million | +115.94% |
| 2023-10-31 | $1.16 Million | +328.80% |
| 2022-10-31 | $-507.86K | +58.49% |
| 2021-10-31 | $-1.22 Million | +64.39% |
| 2020-10-31 | $-3.44 Million | -236.01% |
| 2019-10-31 | $-1.02 Million | -613.60% |
| 2018-10-31 | $199.07K | +712.35% |
| 2017-10-31 | $24.51K | -99.08% |
| 2016-10-31 | $2.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sona Nanotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2154087900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $25.25 Million | 1006.50% |
| Total Equity | $2.51 Million | 100.00% |
Sona Nanotech Inc Competitors by Market Cap
The table below lists competitors of Sona Nanotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CYANCONNODE HLDGS LS-02
F:CUAN
|
$18.14 Million |
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
$18.14 Million |
|
Plenitude Bhd
KLSE:5075
|
$18.14 Million |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
$18.15 Million |
|
Teads B.V.
NASDAQ:TEAD
|
$18.13 Million |
|
SGC eTEC E&C Co. Ltd
KQ:016250
|
$18.13 Million |
|
Aegis Brands Inc
PINK:SCUPF
|
$18.12 Million |
|
Yong Shun Chemical Co Ltd
TWO:4711
|
$18.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sona Nanotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,161,967 to 2,509,110, a change of 1,347,143 (115.9%).
- Net loss of 2,703,957 reduced equity.
- New share issuances of 3,700,750 increased equity.
- Other factors increased equity by 350,350.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.70 Million | -107.77% |
| Share Issuances | $3.70 Million | +147.49% |
| Other Changes | $350.35K | +13.96% |
| Total Change | $- | 115.94% |
Book Value vs Market Value Analysis
This analysis compares Sona Nanotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-10-31 | $0.00 | $0.19 | x |
| 2017-10-31 | $0.00 | $0.19 | x |
| 2018-10-31 | $0.00 | $0.19 | x |
| 2019-10-31 | $-0.02 | $0.19 | x |
| 2020-10-31 | $-0.06 | $0.19 | x |
| 2021-10-31 | $-0.02 | $0.19 | x |
| 2022-10-31 | $-0.01 | $0.19 | x |
| 2023-10-31 | $0.01 | $0.19 | x |
| 2024-10-31 | $0.02 | $0.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sona Nanotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -107.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-107.77%) is above the historical average (-1363.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -24.01% | 0.00% | 0.00x | 1.81x | $-910.47K |
| 2017 | -9312.91% | 0.00% | 0.00x | 70.82x | $-2.28 Million |
| 2018 | -2610.25% | 0.00% | 0.00x | 15.96x | $-5.22 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.42 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.93 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.24 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.31 Million |
| 2023 | -215.12% | 0.00% | 0.00x | 2.37x | $-2.62 Million |
| 2024 | -107.77% | 0.00% | 0.00x | 1.49x | $-2.95 Million |
Industry Comparison
This section compares Sona Nanotech Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sona Nanotech Inc (SNANF) | $1.01 Million | -24.01% | 1.26x | $18.14 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |